．某化学兴趣小组测定某FeCl₃样品（只含少量FeCl₂杂质）中铁元素的质量分数，按以下实验步骤进行操作：

① 称取a g样品，置于烧杯中；

② 加入适量盐酸和蒸馏水，使样品溶解，然后准确配制成250.00mL溶液；

③量取25.00mL步骤②中配得的溶液，置于烧杯中，加入适量的氯水，使反应完全；

④ 加入过量氨水，充分搅拌，使沉淀完全；

⑤ 过滤，洗涤沉淀；

⑥ 将沉淀转移到某容器内，加热、搅拌，直到固体由红褐色全部变为红棕色后，在干燥器中冷却至室温后，称量；

⑦……。

请根据上面叙述，回答：

（1）上图所示仪器中，本实验步骤①②③中必须用到的仪器是E和          （填字母）。 

（2）写出步骤④中发生反应的离子方程式                                    。

（3）样品中的杂质Fe²⁺有较强的还原性，完成并配平下列反应的离子方程式

Fe²⁺  +  ClO₃^— +        ＝  Fe³⁺ +  Cl^— +  H₂O

从理论上分析，上述实验中若将氯水改为NaClO₃时，对实验结果造成       （填偏大、偏小或不影响），

（4）若容器质量是W₁ g，最终容器和固体的总质量是W₂ g，则样品中铁元素的质量分数为                                     。（列出算式，不需化简）

Celebrate. Celebrate. Physicians are delighted with a Food and Drug Administration (FDA) advisory panel’s recommendation earlier this year that Vioxx and its cousins Bextra and Celebrex (all medicines known as Cox-2 inhibitors) should remain on the market, despite evidence they increase heart disease risk in some people. The panelists reached their decision after weighing all the data and concluding the benefits of these pain-relieving drugs outweighed the risks.
Specifically, these scientists acknowledged that, for some patients, these prescription drugs were uniquely effective in reducing pain from arthritis and other causes. For others—concerned about ulcers associated with aspirin and other OTC analgesics—the Cox-2 inhibitors offered the advantage of minimizing potentially serious effects of stomach irritation.
Now is an appropriate time for everyone to take a fresh look at the benefit-risk equation for Vioxx and the other Cox-2 inhibitors.
The risks-increased risk of heart disease in some who use the drugs—have been well publicized. Much less publicity has been given to a spectrum of real and potential benefits that go way beyond reduced risk of stomach irritation. These little-discussed benefits would have been lost, perhaps permanently-had Vioxx, Bextra and Celebrex been driven from shelves in pursuit of perfect safety, an unattainable goal.
For example, there is substantial evidence Cox-2 inhibitors can reduce development of colon polyps, which may become colon canceL Indeed. Celebrex is FDA-approved for those genetically prone to colon cancer. Ironically, the 2004 study that revealed the elevated heart attack risk of Vioxx was primarily designed to further establish the drug’s effectiveness in protecting against colon cancer. And while the results of that interrupted trial have not yet been published, there is good reason to believe they will confirm the protective effects against colon cancer established in research over the last 10 years.
At the time of its withdrawal from the market last fall, studies of Vioxx as well as the other Cox-2 drugs suggest that they had other anti-cancer properties as well, possibly reducing the risk of malignancies of a number of sites, including the lung and esophagus.
Had these drugs been dismissed, their untapped promise for prevention would have evaporated well before it was evaluated and applied to save lives. Fortunately, cooler and wiser heads prevailed.

Cox-2 inhibitors were once banned from the market because they were found to increase the risk of triggering ______.

A．colon cancer

B．stomach problems

C．heart disease

D．genetic problems